for Cancer.
Helping your immune system recognize and fight cancer
cells from within.
A comprehensive clinical guide explaining checkpoint mechanisms, patient
candidacy, clinical timelines, and realistic expectations guided by surgical
oncology expertise.
natural defense.
it.”
Tumors deploy molecular decoys known as immune checkpoints to deactivate
white blood cells. Immunotherapy breaks this camouflage, turning defense
back into active response.
“Immunotherapy is a category of
cancer treatment that empowers
your own immune system to
identify, track, and destroy
malignant cells.”
Unlike traditional treatments that attack rapidly dividing cells directly with
toxic compounds or ionizing radiation, immunotherapy acts as biological
education for your white blood cells.
By counteracting the camouflage proteins that tumor microenvironments
generate, it restores the patient’s own immune surveillance machinery to
keep fighting, sometimes establishing enduring immunological memory.
Mechanism Note: When PD-1 on the immune cell binds to PD-L1 on the cancer
cell, the immune response is turned off. Therapeutic antibodies physically
intercept this union.
for You?
Immunotherapy is never prescribed randomly. Our multidisciplinary tumor board navigates an
interconnected 6-point clinical evaluation matrix to determine if your specific tumor will respond.
Cancers with established immunotherapy protocols include lung,
melanoma, bladder, kidney, triple-negative breast, and GI tract
malignancies.
Administered in advanced, metastatic diseases, or increasingly as
adjuvant treatment post-resection to eliminate microscopic
circulating cells.
Biopsy tissue undergoes immunohistochemistry: PD-L1 TPS score,
MSI-H / dMMR status, and Tumor Mutational Burden (TMB-High).
Evaluating what previous surgeries, chemotherapies, or radiation
doses have occurred to formulate the safest combination
regimen.
Screening for preexisting severe autoimmune disorders (Lupus,
Crohn’s) along with renal and hepatic tolerance metrics.
Immunotherapy is not suitable for every cancer patient. Every single protocol is scientifically
matched to unique tumor biology and approved clinical guidelines. Dr. Sunil Navalgund reviews
individual histology before recommending any immune regimen.
Chemotherapy
While both are systemic treatments, their biological mechanisms and clinical impact differ
completely.
Empowers your body’s white blood cells to recognize and destroy
cancer.
Does not attack cells directly. Instead, it reconfigures the body’s
immune system to overcome tumor stealth mechanisms.
throughout the body.
Chemical agents interfere with cell division processes to kill growing
cells, regardless of whether they are malignant or healthy.
Clinical Insight: In many current oncology protocols (such as non-small cell lung cancer), both therapies are administered concurrently for enhanced synergistic response.
Click each clinical question to mark it off as you prepare for your consultation:
Is immunotherapy appropriate for my specific type and stage of cancer?
Do I need specific biomarker testing (PD-L1, MSI, or NGS) prior to starting?
What is the specific goal of this treatment (curative, adjuvant, or disease control)?
What immune-related symptoms should prompt an immediate call to your clinic?
When and how will we evaluate whether the treatment is successfully working?
Information
Under the clinical leadership of Dr. Sunil Navalgund, ONCOXPERT delivers evidence-
based multidisciplinary cancer care. With extensive fellowship training in advanced
surgical oncology and minimally invasive cancer surgery, Dr. Navalgund works hand-in-
hand with medical and radiation oncologists to sequence immunotherapies precisely
when they provide the highest surgical or systemic benefit.
Treatment?
Every cancer is biologically unique. Your personalized roadmap should be
formulated around your specific histopathology, molecular biomarkers, stage,
and individual personal health.
Consultation
Opinion
From stealth immunosuppression to precision reactivation: follow the cellular milestone
pathway.
White blood cells and
Cytotoxic T-cells continuously scan organs for abnormal
genomic variations and cell mutations.
Detection
Malignant tumors produce PD- L1 and inhibitory ligands,
signaling T-cells to power
down and avoid attack.
Antibody medicines bind
specifically to checkpoint
receptors (PD-1, CTLA-4),
blocking the cancer cell’s
stealth signal.
With brakes released, the host
immune army recognizes tumor
neoantigens and activates
targeted cellular destruction.
Immunotherapy is administered in streamlined, predictable outpatient cycles designed
to minimize disruption to your daily life.
Biomarker verification, blood panel
reviews, baseline radiographic imaging,
and multidisciplinary tumor board
recommendation.
Given as an IV Infusion over 30 to 90
minutes in a comfortable day clinic.
Occasional drugs given via
subcutaneous injection or oral pills.
Continuous symptom check-ins, routine
hormone/thyroid blood draws, and
scheduled CT or PET scans every 8–12
weeks.
Long-term disease control evaluation.
Many patients remain on active therapy
for up to 2 years if disease remains
stable.
Because immunotherapy stimulates the immune system, healthy organs may sometimes
experience temporary inflammation. Recognizing symptoms early ensures rapid clinical
management.
Feeling persistently tired or with
diminished energy that doesn’t
fully improve with rest.
Mild itching, rashes, or dry
patches responding readily to
topical corticosteroid creams.
Breath
inflammation) requiring
immediate oncology alert.
or Bowel
Changes
stools or
cramping
indicating mild
colitis,
managed with
anti-
inflammatories.
Symptoms
Low-grade fever, chills, or
headache following infusion that
generally settles in 24 hours.
Mild arthralgia or muscular
discomfort that is safely managed
with supportive care.
Patient Golden Rule: Always report new or changing symptoms to Dr. Sunil Navalgund’s nursing
coordinator immediately rather than waiting for your next routine cycle.
“Immunotherapy can produce profound, durable, and sometimes long-lasting
remissions in responsive patients. However, it does not work for everyone,
and it is not a universal cure for cancer.”
For patients whose tumors possess high PD-L1
expression or high mutation loads,
immunotherapy has achieved sustained disease
control lasting for years beyond historic
averages.
Some cancers develop molecular resistance or
lack neoantigen targets altogether. Precision
genomics ensure we avoid unnecessary
toxicities when immunotherapy is unlikely to
benefit.
Center for Advanced Surgical Oncology & Comprehensive Cancer
Care, led by Dr. Sunil Navalgund (MS, MCh Surgical Oncology).
Combining surgical precision with next-generation systemic
targeted therapies.
Medical Disclaimer: This portal is prepared strictly for clinical education purposes and does not substitute direct medical
diagnosis, staging, or treatment recommendations. Always seek the advice of your qualified oncologist regarding clinical
conditions.